Concord Drugs share price
BSE: 538965Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 27 Oct 2026. Previous close ₹65.07.
27 Oct: open ₹69.00, high ₹69.00, low ₹63.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹84 Cr3,001st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 41.12
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.28
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 5,482
Results
Standalone, as consolidated accounts are on record for only 4 of the last ten years; ₹ crore.Concord Drugs quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +82.5%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +380.5%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹21 Crdown 41.25%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1.11 Crup 115.27%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 5.3%
Revenue by quarter
Net profit by quarter, a loss in red
- Net profit
- Loss
The quarters either side of a change of basis do not compare. From the quarter to Mar 2025, the company's revenue for the year to Mar 2025, ₹37 Cr, differs from its quarters added, ₹30 Cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.8 | 10.8 | 0.8 | 13.4 | 10.1 | 16.8 | 35.6 | 20.9 |
| Net profit | 0.1 | 0.2 | −7.2 | 0.1 | 0.2 | 0.2 | 0.5 | 1.1 |
| Net margin | 0.5% | 2.1% | −902.0% | 0.8% | 1.9% | 1.3% | 1.5% | 5.3% |
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹76 Crup 105.37%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1.04 Crup 250.83%
- Net margin
- 1.4%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2025, the company's revenue for that year, ₹37 Cr, differs from its quarters added, ₹30 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.5 | 51.8 | 48.1 | 51.3 | 51.4 | 59.0 | 51.3 | 43.3 | 36.9 | 75.8 |
| Net profit | 0.2 | 0.3 | 0.4 | 0.3 | 3.3 | 1.6 | 0.9 | 0.4 | 0.3 | 1.0 |
| Net margin | 0.3% | 0.6% | 0.8% | 0.6% | 6.4% | 2.7% | 1.7% | 1.0% | 0.8% | 1.4% |
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacture of Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/B: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned. Dividend yield is not shown: no dividend in the years on record. Its history crosses a change of basis in the accounts in the year to Mar 2025: days before it are of the company before the change.Concord Drugs PE ratio and valuation
At or below today's level on 54% of 1,073 trading days over the last 5 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +126.0% | +250.8% | −35.6% | 0.0% |
| 3 years | +36.8% | +2.7% | +33.2% | 0.0% |
| 5 years | +19.3% | −22.7% | +54.3% | 0.0% |
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Concord Drugs insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 6 off-market moves
Concord Drugs competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Concord Drugs in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Vaishali PharmaVAISHALI | 96 | 21.63 | 1.39 | – | – | 6.6% | 4.2% | 0.00% |
 Parmax PharmaPARMAX | 93 | – | – | −17.6% | – | – | −70.0% | 0.00% |
 Mercury LaboratoriesMERCURYLAB | 90 | 21.61 | 1.55 | −3.7% | +10.4% | 7.5% | 7.0% | 0.47% |
 Amwill Health CareAMWILL | 86 | 7.67 | 1.03 | +21.4% | +38.7% | 14.4% | – | 1.16% |
 Denis Chem LabDENISCHEM | 84 | 10.50 | 0.92 | +4.1% | −5.8% | 9.0% | 10.4% | 4.14% |
 Samrat PharmachemSAMRATPH | 83 | – | 1.22 | +4.7% | −145.8% | −3.2% | −2.7% | 0.00% |
 Cian HealthcareCHCL | 79 | – | 9.25 | −8.1% | – | −113.9% | – | 0.00% |
 Vilin Bio MedVILINBIO | 78 | 40.20 | 2.73 | +185.4% | +763.0% | 7.5% | – | 0.00% |
Latest announcements
Routine notices left out.Concord Drugs announcements
Oct 2026
1 Oct · Meeting
Sep 2026
30 Sep · Meeting
7 Sep · Letter To Shareholders
7 Sep · Meeting
7 Sep · Meeting
7 Sep · Meeting
Concord Drugs share price by year
Each calendar year to 2025.Concord Drugs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 82.48 | +118.8% | 88.15 | 27.46 |
| 2024 | 37.70 | −36.9% | 56.11 | 32.47 |
| 2023 | 59.72 | +83.5% | 59.72 | 26.15 |
| 2022 | 32.55 | +1.2% | 38.25 | 21.25 |
| 2021 | 32.15 | +40.4% | 42.85 | 21.75 |
| 2020 | 22.90 | +52.7% | 31.25 | 12.29 |
| 2019 | 15.00 | −33.6% | 24.05 | 13.00 |
| 2018 | 22.60 | −29.4% | 32.55 | 17.00 |
| 2017 | 32.00 | −34.7% | 69.45 | 27.10 |
| 2016 | 49.00 | −17.7% | 72.00 | 42.25 |
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 26 Oct 2026 | 74.50 | 74.50 | 65.02 | 65.07 | 66.28 | 3,528 |
| 23 Oct 2026 | 67.62 | 70.00 | 65.00 | 68.06 | 67.51 | 1,703 |
| 22 Oct 2026 | 68.00 | 69.00 | 65.00 | 69.00 | 67.41 | 1,127 |
| 21 Oct 2026 | 72.78 | 72.78 | 66.50 | 66.77 | 66.95 | 3,322 |
| 19 Oct 2026 | 68.40 | 69.00 | 66.50 | 68.00 | 68.15 | 2,775 |
| 16 Oct 2026 | 73.97 | 73.97 | 66.30 | 68.40 | 70.65 | 4,885 |
| 15 Oct 2026 | 70.10 | 72.40 | 69.50 | 71.69 | 71.36 | 782 |
| 14 Oct 2026 | 73.99 | 73.99 | 70.50 | 70.51 | 71.33 | 3,299 |
| 13 Oct 2026 | 70.50 | 72.50 | 70.10 | 71.40 | 71.54 | 2,288 |
Company details
- BSE code
- 538965
- ISIN
- INE858L01010
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.concorddrugs.in
- CIN
- L24230TG1995PLC020093
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1995
- Registered office
- Survey No.249, Brahmanpally Village, Hayatnagar Mandal, R.R. Dist, Hyderabad 501511, Telangana
- Share registrar
- Aarthi Consultants Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments